Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand
Background: Maternal antibodies, acquired passively via placenta and/or breast milk, may contribute to the reduced efficacy of oral rotavirus vaccines observed in children in developing countries. This study aimed to investigate the effect of rotavirus specific maternal antibodies on the serum IgA r...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-05-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2016.1274474 |
| _version_ | 1797674540611928064 |
|---|---|
| author | Mee-Yew Chen Carl D. Kirkwood Julie Bines Daniel Cowley Daniel Pavlic Katherine J. Lee Francesca Orsini Emma Watts Graeme Barnes Margaret Danchin |
| author_facet | Mee-Yew Chen Carl D. Kirkwood Julie Bines Daniel Cowley Daniel Pavlic Katherine J. Lee Francesca Orsini Emma Watts Graeme Barnes Margaret Danchin |
| author_sort | Mee-Yew Chen |
| collection | DOAJ |
| description | Background: Maternal antibodies, acquired passively via placenta and/or breast milk, may contribute to the reduced efficacy of oral rotavirus vaccines observed in children in developing countries. This study aimed to investigate the effect of rotavirus specific maternal antibodies on the serum IgA response or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in parallel to a Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. At the time of the study rotavirus vaccines had not been introduced in New Zealand and the burden of rotavirus disease was evident. Methods: Rotavirus specific IgG and serum neutralizing antibody (SNA) levels in cord blood and IgA levels in colostrum and breast milk samples collected ∼4 weeks, ∼20 weeks and ∼28 weeks after birth were measured. Infants were randomized to receive the first dose of vaccine at 0–5 d (neonatal schedule) or 8 weeks (infant schedule). Breast feeding was with-held for 30 minutes before and after vaccine administration. The relationship between rotavirus specific IgG and SNA levels in cord blood and IgA in colostrum and breast milk at the time of first active dose of RV3-BB vaccine and level of IgA response and stool excretion after 3 doses of vaccine was assessed using linear and logistic regression. Results: Forty infants received 3 doses of RV3-BB rotavirus vaccine and were included in the analysis of the neonatal and infant groups. Rotavirus specific IgA in colostrum (neonatal schedule group) and breast milk at 4 weeks (infant schedule group) was identified in 14/21 (67%) and 14/17 (82%) of infants respectively. There was little evidence of an association between IgA in colostrum or breast milk IgA at 4 weeks, or between cord IgG or SNA level, and IgA response or stool excretion after 3 doses of RV3-BB, or after one dose (neonatal schedule) (all p>0.05). Conclusions: The level of IgA in colostrum or breast milk and level of placental IgG and SNA did not impact on the serum IgA response or stool excretion following 3 doses of RV3-BB Rotavirus Vaccine administered using either a neonatal or infant schedule in New Zealand infants. |
| first_indexed | 2024-03-11T22:01:35Z |
| format | Article |
| id | doaj.art-4a688f9055a54de19eca538b3f7db1e1 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:01:35Z |
| publishDate | 2017-05-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-4a688f9055a54de19eca538b3f7db1e12023-09-25T11:00:55ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2017-05-011351126113510.1080/21645515.2016.12744741274474Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New ZealandMee-Yew Chen0Carl D. Kirkwood1Julie Bines2Daniel Cowley3Daniel Pavlic4Katherine J. Lee5Francesca Orsini6Emma Watts7Graeme Barnes8Margaret Danchin9Dunedin School of Medicine, University of OtagoRV3 Rotavirus Vaccine Program, Murdoch Childrens Research InstituteRV3 Rotavirus Vaccine Program, Murdoch Childrens Research InstituteRV3 Rotavirus Vaccine Program, Murdoch Childrens Research InstituteRV3 Rotavirus Vaccine Program, Murdoch Childrens Research InstituteRV3 Rotavirus Vaccine Program, Murdoch Childrens Research InstituteRV3 Rotavirus Vaccine Program, Murdoch Childrens Research InstituteRV3 Rotavirus Vaccine Program, Murdoch Childrens Research InstituteRV3 Rotavirus Vaccine Program, Murdoch Childrens Research InstituteRV3 Rotavirus Vaccine Program, Murdoch Childrens Research InstituteBackground: Maternal antibodies, acquired passively via placenta and/or breast milk, may contribute to the reduced efficacy of oral rotavirus vaccines observed in children in developing countries. This study aimed to investigate the effect of rotavirus specific maternal antibodies on the serum IgA response or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in parallel to a Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. At the time of the study rotavirus vaccines had not been introduced in New Zealand and the burden of rotavirus disease was evident. Methods: Rotavirus specific IgG and serum neutralizing antibody (SNA) levels in cord blood and IgA levels in colostrum and breast milk samples collected ∼4 weeks, ∼20 weeks and ∼28 weeks after birth were measured. Infants were randomized to receive the first dose of vaccine at 0–5 d (neonatal schedule) or 8 weeks (infant schedule). Breast feeding was with-held for 30 minutes before and after vaccine administration. The relationship between rotavirus specific IgG and SNA levels in cord blood and IgA in colostrum and breast milk at the time of first active dose of RV3-BB vaccine and level of IgA response and stool excretion after 3 doses of vaccine was assessed using linear and logistic regression. Results: Forty infants received 3 doses of RV3-BB rotavirus vaccine and were included in the analysis of the neonatal and infant groups. Rotavirus specific IgA in colostrum (neonatal schedule group) and breast milk at 4 weeks (infant schedule group) was identified in 14/21 (67%) and 14/17 (82%) of infants respectively. There was little evidence of an association between IgA in colostrum or breast milk IgA at 4 weeks, or between cord IgG or SNA level, and IgA response or stool excretion after 3 doses of RV3-BB, or after one dose (neonatal schedule) (all p>0.05). Conclusions: The level of IgA in colostrum or breast milk and level of placental IgG and SNA did not impact on the serum IgA response or stool excretion following 3 doses of RV3-BB Rotavirus Vaccine administered using either a neonatal or infant schedule in New Zealand infants.http://dx.doi.org/10.1080/21645515.2016.1274474maternal antibodiesrotavirus vaccinesefficacydeveloping countries |
| spellingShingle | Mee-Yew Chen Carl D. Kirkwood Julie Bines Daniel Cowley Daniel Pavlic Katherine J. Lee Francesca Orsini Emma Watts Graeme Barnes Margaret Danchin Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand Human Vaccines & Immunotherapeutics maternal antibodies rotavirus vaccines efficacy developing countries |
| title | Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand |
| title_full | Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand |
| title_fullStr | Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand |
| title_full_unstemmed | Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand |
| title_short | Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand |
| title_sort | rotavirus specific maternal antibodies and immune response to rv3 bb neonatal rotavirus vaccine in new zealand |
| topic | maternal antibodies rotavirus vaccines efficacy developing countries |
| url | http://dx.doi.org/10.1080/21645515.2016.1274474 |
| work_keys_str_mv | AT meeyewchen rotavirusspecificmaternalantibodiesandimmuneresponsetorv3bbneonatalrotavirusvaccineinnewzealand AT carldkirkwood rotavirusspecificmaternalantibodiesandimmuneresponsetorv3bbneonatalrotavirusvaccineinnewzealand AT juliebines rotavirusspecificmaternalantibodiesandimmuneresponsetorv3bbneonatalrotavirusvaccineinnewzealand AT danielcowley rotavirusspecificmaternalantibodiesandimmuneresponsetorv3bbneonatalrotavirusvaccineinnewzealand AT danielpavlic rotavirusspecificmaternalantibodiesandimmuneresponsetorv3bbneonatalrotavirusvaccineinnewzealand AT katherinejlee rotavirusspecificmaternalantibodiesandimmuneresponsetorv3bbneonatalrotavirusvaccineinnewzealand AT francescaorsini rotavirusspecificmaternalantibodiesandimmuneresponsetorv3bbneonatalrotavirusvaccineinnewzealand AT emmawatts rotavirusspecificmaternalantibodiesandimmuneresponsetorv3bbneonatalrotavirusvaccineinnewzealand AT graemebarnes rotavirusspecificmaternalantibodiesandimmuneresponsetorv3bbneonatalrotavirusvaccineinnewzealand AT margaretdanchin rotavirusspecificmaternalantibodiesandimmuneresponsetorv3bbneonatalrotavirusvaccineinnewzealand |